• 목록
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

depression Treatment without medicines Treatment Breakthroughs

Scientists are taking on depression from different ways than they did before. These approaches are designed to aid in avoiding relapses and identify the appropriate medication.

If your depression isn't responding to antidepressants, psychotherapy may be beneficial. These include cognitive behavioral therapy as well as psychotherapy with others.

Deep Brain Stimulation

Deep brain stimulation (DBS) is a surgical procedure in which electrodes are placed inside the brain to target specific brain regions which cause disorders and conditions like depression. The electrodes connect to the device that emits electric pulses to treat the disease. The DBS device is known as a neurostimulator. It can also be used to treat other neurological disorders, such as essential tremor, Parkinson's disease and epilepsy. The DBS device's pulsing may "jam up" circuits that cause abnormal brain activity during depression, while leaving other circuits unaffected.

Clinical trials of DBS for depression have revealed significant improvement in patients suffering from treatment-resistant depression (TRD). Despite the positive results however, the path to steady recovery from TRD looks different for every patient. Clinicians rely on subjective reports from patient interviews and psychiatric ratings scales that can be difficult for them to interpret.

Researchers from the Georgia Institute of Technology, Emory University School of Medicine and the Icahn School of Medicine at Mount Sinai, have developed an algorithm that can detect subtle changes in brain activity patterns and can differentiate between stable and depressive recovery states. The research of the scientists was published in Nature Human Behaviour, exemplifies the importance of combining neuroscience, medicine and computer engineering disciplines to develop potentially life-changing therapies.

During DBS procedures, doctors insert a thin wire-like lead into the brain through a tiny hole in the skull. The lead is fitted with electrodes that transmit electrical signals to the brain. It then connects to an extension wire that runs from the brain, up the neck and behind the ear down to the chest. The extension wire and the lead are connected to a stimulator powered by batteries implanted under the skin of the chest.

The programmable neurostimulator produces electrical impulses to regulate abnormal brain activity in the areas targeted by the DBS devices. In the study, the team employed DBS to target a region of the brain known as the subcallosal cingulate cortex (SCC). Scientists found that stimulating the SCC resulted in an increase in dopamine levels, which could help alleviate depression symptoms.

Brain Scanners

A doctor can employ a variety tools and techniques to diagnose depression, but a brain scan is the most effective. This technique employs imaging to observe changes at structural and function levels of brain activity. It is able to pinpoint the regions of a patient's brain that are affected by the disorder and determine what is happening in those areas in real-time.

Brain mapping can help to predict the type of treatment that is most effective for an person. For instance, certain people are more responsive to antidepressant drugs than others, however this isn't always the case. Psychologists and doctors can prescribe medications more precisely by using MRI to measure the effectiveness. Seeing how their treatment is progressing can also encourage better compliance.

The difficulty of measuring mental health has hampered research despite its widespread prevalence. There is a wealth of information on moderate depression treatment anxiety, depression, and other disorders. However it's been difficult to determine what causes them. Technology is now uncovering the underlying causes of these disorders.

A recent study published in Nature Medicine, for example classified depression into six distinct subtypes. This opens the door to personalized treatment.

Researchers used fMRI to examine the brain activity of 801 individuals with depression and 137 people who were not. They examined the connectivity and activation of brain circuits affected by depression, including those that regulate emotions and cognition. They examined the brain scans of a subject in a state of rest and while completing specific tasks.

The results showed that a combination of resting-state and task-based tests could be used to predict whether or not someone would react to SSRIs. This is the first time that a predictive test has been developed in the field of psychiatry. The team is now working to develop an automated instrument that can make these predictions.

This is especially useful for those who don't respond to standard treatments like therapy and medication. Up to 60% of those suffering from depression do not respond to their first treatment. Some of those patients are classified as resistant to treatment and are difficult to treat with standard treatment however, the hope is that new technology will aid to optimize treatment options.

Brain Implants

Sarah suffered from a debilitating form of depression. She described it as a black hole that dragged her down. It was so strong that she was unable to move. She had tried all sorts of medications but none of them gave an enduring lift. She had also undergone other treatments such as electroconvulsive therapy and ketamine infusions but both failed to work. She decided to undergo surgery in order to implant electrodes in her brain to send her a targeted shock whenever she was about have an attack of depression.

Deep brain stimulation is a method that is used extensively in the treatment of Parkinson's disease. It has also been shown to be helpful for some people who are unable to respond to treatment. It's not an effective treatment, but it helps the brain cope. It makes use of a device to implant tiny electrodes into specific parts of the mind such as a pacemaker.

In a study published in Nature Medicine on Monday, two researchers from the University of California at San Francisco describe their experience using a DBS to tailor depression treatment for a particular patient. They described it as a "revolutionary" new treatments for depression approach that could pave the way for a more flexible DBS treatments for other patients.

The team studied Sarah's brain circuitry, and discovered that her amygdala was the main cause of her postnatal depression treatment episodes. They found that a specific area deep in her brain --- the ventral striatum -is responsible for calming the amygdala's overreaction. Then, they inserted a matchbox-sized device into Sarah's skull and strung its spaghetti-like electrode legs down to these two regions.

Now, when a symptom of depression occurs the device tells Sarah's brain to send a tiny electrical charge to the amygdala as well as to the ventral striatum. The intention is to reduce depression and help her to be more positive. It is not a cure for depression however, it can make a huge difference for the people who require it the most. In the future it may be used to identify the biological signs that indicates a depression is on the way and allow doctors to prepare by turning up the stimulation.

Personalized Medicine

The concept of personalized medicine refers to tailoring prevention, diagnosis and treatment strategies for individual patients based on the information gathered through molecular profiling, medical imaging, lifestyle information and so on. This differs from conventional treatments, which are developed to fit an average patient.

Recent studies have revealed a myriad of factors that contribute to depression among different patients. These include genetic variations, neural circuitry dysfunctions biomarkers and psychosocial markers, among others. Personalized psychiatry aims to integrate these findings into clinical decision-making for optimal treatment. It also aims to help develop individualized treatment approaches for psychiatric disorders such as depression, aiming at a better utilization of resources and improving patient outcomes.

The field of individualized psychiatry continues to grow but there are a few obstacles still preventing its clinical application. Many psychiatrists are not familiar with the pharmacological profile of antidepressants, which can lead to suboptimal prescribing. In addition the cost and complexity of integrating multiomics data into healthcare systems, as well as ethical considerations must be taken into account.

A promising avenue for advancing the concept of personalized psychiatry is pharmacogenetics, which works at using the individual's unique genetic profile to determine the appropriate dose of medication. This can help reduce the side effects of medications and boost the effectiveness of treatment, especially with SSRIs.

However, it is important to emphasize that this is only an option and requires more research before it is widely accepted. Other factors, like lifestyle choices and environmental influences, are also important to consider. The integration of pharmacogenetics and lifestyle choices in depression treatment should therefore be carefully balanced.

Functional neuroimaging is a further promising method for guiding the choice of antidepressants and psychotherapy. Studies have shown that the pretreatment activation levels of specific neural circuitries (e.g. ventral and pregenual anterior cingulate cortex) predict the response to psychotherapeutic and pharmacological treatments. Additionally, certain clinical trials have already used these findings to help select participants, focusing on those with greater levels of activation and thus having more favorable responses to therapy.